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Longitudinal growth following treatment for osteosarcoma
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Abstract
Purpose. The purpose of this study was to analyse the height at diagnosis and growth in 72 skeletally immature children
who had been treated for osteosarcoma in the area of the knee.
Subjects. Of the patients, the average age at diagnosis was 10 years in girls and 12 years in boys. All children received
neo-adjuvant chemotherapy, and had limb salvage by endoprosthetic replacement.
Results and conclusion. The results of this study indicate that there is no evidence that children with osteosarcoma are
taller at diagnosis than their normal counterparts. However, there was a marked retardation in growth in the year following
the administration of cytotoxic chemotherapy. There were 19 children who reached skeletal maturity. The ® nal height in
these children was not signi® cantly different from the normal population.
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Introduction
It has been reported that children with osteosarcoma
are taller than their normal counterparts.
1 However,
this has been contradicted by others.
2,3
Glasser et al.
2 showed that children with malignant
primary bone tumours had a marked retardation in
growth during the year of cytotoxic chemotherapy.
They also suggested that their ® nal height might be
affected.
It was the purpose of this study to analyse the
height at diagnosis and the growth that had occurred
in skeletally immature children with an osteosarcoma
around the knee who have been treated by limb
salvage at our centre.
Subjects and methods
All skeletally immature children who were diagnosed
between 1981 and 1994 as having an osteosarcoma
in the area of the knee, that had been treated at our
centre by limb-salvage surgery, were included in this
study. Patients were excluded if they died within 1.5
years of diagnosis, or if height measurements were
unavailable.
At diagnosis, all patients were fully staged and had
their bone age estimated according to the Greulich
and Pyle
4 method. Height was also measured in the
patients, while standing with a level pelvis.
5
Following diagnosis, all patients received neo-
adjuvant chemotherapy according to the then cur-
rent protocol. This was normally cisplatinum and
doxorubicin or cisplatinum, doxorubicin and high-
dose methotrexate.
6
After three cycles of chemotherapy (usually 9
weeks following diagnosis), patients were restaged
and underwent limb-salvage surgery. Limb salvage
was performed by resection of the tumour and endo-
prosthetic replacement. The expected growth in the
resected segment was calculated with the aid of the
bone age and data provided by Tupman.
7 If the
expected growth in the resected segment exceeded
3 cm, an extensible endoprosthetic replacement was
inserted,
8± 10 otherwise a non-extensible replacement
that allowed some normal growth to continue was
used.
10± 12
Patients were discharged after 2 weeks and had a
further three cycles of chemotherapy. All children
were followed-up in the outpatient clinic and had
their height estimated at regular intervals until they
reached skeletal maturity. Children who had an
extensible prosthesis had regular lengthenings in
order to maintain limb length equality. On average,
two lengthening operations per year, from time of
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diagnosis until they reached skeletal maturity, were
performed.
13
The heights at diagnosis of all children were plot-
ted in the growth charts for British children
14,15
according to guidelines given by Cole.
16
The children were split into three groups. One
group of patients below the 25th percentile, one
group between the 25th and 75th percentiles and
one group above the 75th percentile. Statistical
analysis was performed with the aid of the Chi-
square test.
The heights of the children 1 and 5 years follow-
ing diagnosis, and at skeletal maturity, were also
plotted in the growth charts. Statistical analysis was
performed in a manner identical to that described
above.
The standard deviation score (or Z score) is the
actual height of the patient minus the mean height
of the population for that chronological age divided
by the appropriate standard deviation. Therefore, a
standard deviation score of 0 indicates that the
patient has an average height for age and gender.
Similarly, a child with a score of 1 1, is one stan-
dard deviation above average for age and gender.
The difference in standard deviation score at diag-
nosis and 1 year following treatment is a measure for
the velocity of growth. A difference in standard
deviation score of 0 indicates that the child had an
average velocity of growth for that age range.
The standard deviation score was calculated for
all patients who had their height estimated at diag-
nosis and after 1 year following treatment. The
difference in standard deviation score after 1 year
was calculated (negative is a decrease in standard
deviation score). Similarly, the difference in stan-
dard deviation score was calculated 5 years follow-
ing treatment and at skeletal maturity.
All patients had their bone age estimated at time
of diagnosis. The bone age was estimated according
to the method described by Greulich and Pyle
4 and
compared to chronological age.
Results
Seventy-two children were identi® ed from the medi-
cal records. There were 47 boys and 25 girls. The
average age at diagnosis was 12.1 years (range 5.8±
15.3) in boys and 9.9 years (range 5.8± 13.5) in girls.
In 35 cases the left leg was affected and in 37 cases
the right leg. There were 45 children who had a
distal femoral, and 27 who had a proximal tibial,
osteosarcoma. Limb salvage was by an endopros-
thetic replacement that could be lengthened in 50
children. The remaining 22 children had an endo-
prosthetic replacement that could not be length-
ened, but that allowed for some growth to
continue.
10± 12
All children received neo-adjuvant chemotherapy.
Forty-three children received cisplatinum and dox-
orubicin only, and 17 children received cisplatinum
Fig. 1. Difference in bone age and chronological age at diagnosis
in 72 children with an osteosarcoma in the area of the knee. A
negative value indicates that the bone age was less than the
chronological age.
and doxorubicin in combination with high-dose
methotrexate.
6 Of the remaining 12 children, nine
had chemotherapy according to the regime pro-
posed by Rosen et al.
17 and three children had
alternative treatment protocols.
There were 22 children who eventually died.
Twenty deaths were due to metastatic disease, one
due to doxorubicin-induced cardiomyopathy, and
one patient died due to extensive ileofemoral throm-
bosis. All but one patient died within 5 years of
diagnosis, but no patient died prior to 1.5 years
following diagnosis.
The bone age at diagnosis was on average 9.7
years (range 6± 13) in girls and 11.3 years (range
5± 14) in boys. As can be seen in Fig. 1, the vast
majority of children had a bone age that was less
than the chronological age (on average 0.25 years in
girls and 0.73 years in boys). This difference was
statistically signi® cant (sign test, p , 0.05).
There were 63 patients who had their height
estimated at diagnosis. The results are shown in Fig.
2. There was no statistically signi® cant differenceLongitudinal growth following treatment for osteosarcoma 117
Fig. 2. Height at diagnosis in 63 children with an osteosarcoma
in the area of the knee plotted in the growth charts for the normal
population.
14,15
Fig. 3. Height 1 year following diagnosis in 50 children who
received neo-adjuvant chemotherapy for an osteosarcoma in the
area of the knee plotted in the growth charts for the normal
population.
14,15
between the children in our study and the popu-
lation norm.
14,15
In 50 children, the height was measured 1 year
following diagnosis (Fig 3). The heights in these
children were also not signi® cantly different from
the normal population.
14,15 Forty-one of these 50
children also had their height estimated at diagnosis.
As can be seen in Fig. 4, the vast majority of
children had a standard deviation score that was less
than the standard deviation score at diagnosis. In
girls, the standard deviation score 1 year following
diagnosis was, on average, 0.67 less than that at
diagnosis, whilst this was 0.30 less in boys. This
difference was statistically signi® cant (sign test,
p , 0.05), indicating that chemotherapy causes re-
tardation in growth in the year following treatment.
At 5 years following diagnosis, 18 children had
their height measured. The heights in these children
were also not signi® cantly different from the normal
population.
14,15 Fifteen of these children also had
their height measured at diagnosis. In girls, the
standard deviation score was, on average, 0.17 less
than the standard deviation score at diagnosis. Boys
had a standard deviation score that was on average
0.25 less than that at diagnosis.
There were 19 children in our study who reached
skeletal maturity. The ® nal height in these children
was not signi® cantly different from the normal
population (Fig 5). Sixteen of these children also
had their height estimated at diagnosis. The stan-
dard deviation score in girls who reached skeletal
maturity was, on average, 0.48 higher than that at
diagnosis, whilst this was 0.24 higher in boys.
These results indicate that the surviving children
subsequently make up for the retardation in growth
caused by the chemotherapeutic treatment. Al-
though the number of children who reached skeletal
maturity is relatively small, ® nal height does not
seem to be different from the population norm.
14,15
Discussion
This study failed to reproduce the earlier ® ndings of
Fraumeni,
1 suggesting that children with osteosar-118 W. Paul Cool et al.
Fig. 4. Difference in standard deviation score after 1 year in 41
children who had their height estimated at diagnosis and after 1
year. A negative value indicates that the child had a less than
average growth for age and gender.
Fig. 5. Height at skeletal maturity in 19 children who have
been treated for an osteosarcoma in the area of the knee plotted
in the growth charts for the normal population.
14,15
administration of cytotoxic chemotherapy. This fur-
ther illustrates that actual height is a poor indicator
of growth retardation and that the velocity of growth
is a more sensitive measure.
The ® nal height of the children in this study was
similar to the normal population.
14,15 Furthermore,
the difference in standard deviation score was, on
average, positive. This indicates that these children
subsequently make up for the retardation in growth
caused by the chemotherapy treatment.
In conclusion, there is no evidence that children
with osteosarcoma are taller than their normal coun-
terparts. Growth is retarded in the year following
chemotherapy treatment, but the ® nal height in
these children is not signi® cantly different from the
normal population.
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